The WHO public health approach to HIV treatment and care: looking back and looking ahead

The Lancet Infectious Diseases

Volumn 18, Issue 3, 2018, Pages e76-e86

  Ford, Nathan ^a   Ball, Andrew ^a   Baggaley, Rachel ^a   Vitoria, Marco ^a   Low Beer, Daniel ^a   Penazzato, Martina ^a   Vojnov, Lara ^a   Bertagnolio, Silvia ^a   Habiyambere, Vincent ^a   Doherty, Meg ^a   Hirnschall, Gottfried ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CHRONIC DISEASE; CLINICAL DECISION MAKING; DRUG RESISTANCE; DRUG RESPONSE; EPIDEMIC; HEALTH CARE DELIVERY; HEALTH INSURANCE; HEALTH SERVICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MEDICAL SPECIALIST; PATIENT MONITORING; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; WORLD HEALTH ORGANIZATION; CONTACT EXAMINATION; DIAGNOSTIC IMAGING; PUBLIC HEALTH SERVICE;

CONTACT TRACING; EPIDEMICS; HIV INFECTIONS; HUMANS; PUBLIC HEALTH ADMINISTRATION; WORLD HEALTH ORGANIZATION;

EID: 85044353985     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(17)30482-6     Document Type: Review

References (120)

1. Gilks, CF, Crowley, S, Ekpini, R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 368 (2006), 505–510.
2. WHO. Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach, 2002, World Health Organization, Geneva.
3. WHO. Task shifting: global recommendations and guidelines, 2008, World Health Organization, Geneva.
4. The TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med 373 (2015), 808–822.
5. The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 373 (2015), 795–807.
6. Cohen, MS, Chen, YQ, McCauley, M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365 (2011), 493–505.
7. Schouten, EJ, Jahn, A, Midiani, D, et al. Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach. Lancet 378 (2011), 282–284.
8. Barlow-Mosha, L, Musiime, V, Davies, MA, et al. Universal antiretroviral therapy for HIV-infected children: a review of the benefits and risks to consider during implementation. J Int AIDS Soc 20 (2017), 1–7.
9. Schomaker, M, Leroy, V, Wolfs, T, et al. Optimal timing of antiretroviral treatment initiation in HIV-positive children and adolescents: a multiregional analysis from southern Africa, west Africa and Europe. Int J Epidemiol 46 (2017), 453–465.
10. Kanters, S, Vitoria, M, Doherty, M, et al. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis. Lancet HIV 3 (2016), e510–e520.
11. Ramjan, R, Calmy, A, Vitoria, M, et al. Systematic review and meta-analysis: patient and programme impact of fixed-dose combination antiretroviral therapy. Trop Med Int Health 19 (2014), 501–513.
12. Penazzato, M, Lee, J, Capparelli, E, et al. Optimizing drugs to reach treatment targets for children and adolescents living with HIV. J Int AIDS Soc, 18(suppl 6), 2015, 20270.
13. Rutherford, GW, Anglemyer, A, Easterbrook, PJ, et al. Predicting treatment failure in adults and children on antiretroviral therapy: a systematic review of the performance characteristics of the 2010 WHO immunologic and clinical criteria for virologic failure. AIDS 28:suppl 2 (2014), S161–S169.
14. Kredo, T, Ford, N, Adeniyi, FB, Garner, P, Decentralising HIV treatment in lower- and middle-income countries. Cochrane Database Syst Rev, 6, 2013 CD009987.
15. Kredo, T, Adeniyi, FB, Bateganya, M, Pienaar, ED, Task shifting from doctors to non-doctors for initiation and maintenance of antiretroviral therapy. Cochrane Database Syst Rev, 7, 2014 CD007331.
16. UNAIDS. Ending AIDS. Progress towards the 90-90-90 targets, 2017, The Joint United Nations Programme on HIV/AIDS, Geneva.
17. UNAIDS. 15by15: a global target achieved. http://www.unaids.org/sites/default/files/media_asset/UNAIDS_15by15_en.pdf, 2015 (accessed Sept 29, 2017).
18. Johnson, LF, Mossong, J, Dorrington, RE, et al. Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. PLoS Med, 10, 2013, e1001418.
19. Antiretroviral Therapy Cohort C. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV 8 (2017), e349–e356.
20. UNAIDS. Fast track: ending the AIDS epidemic by 2030. http://www.unaids.org/sites/default/files/media_asset/JC2686_WAD2014report_en.pdf, 2014 (accessed Sept 29, 2017).
21. WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach, 2006, World Health Organization, Geneva.
22. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach, 2013, World Health Organization, Geneva.
23. Perriens, JH, Habiyambere, V, Dongmo-Nguimfack, B, Hirnschall, G, Prices paid for adult and paediatric antiretroviral treatment by low- and middle-income countries in 2012: high, low or just right?. Antivir Ther 19:suppl 3 (2014), 39–47.
24. Ford, N, Mofenson, L, Kranzer, K, et al. Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts. AIDS 24 (2010), 1461–1470.
25. Doherty M, Beusenberg M, Babovic T, et al. Uptake and implementation of the WHO 2015 consolidated ARV guidelines: progress towards treat all. 21st International AIDS Conference; Durban, South Africa; July 18–22, 2016. THPEB057.
26. Keiser, O, Orrell, C, Egger, M, et al. Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Med, 5, 2008, e148.
27. Braitstein, P, Brinkhof, MW, Dabis, F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367 (2006), 817–824.
28. Mills, EJ, Nachega, JB, Buchan, I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 296 (2006), 679–690.
29. The IeDEA and ART Cohort Collaborations. Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr 65 (2014), e8–e16.
30. Inter-Agency Task Team. Paediatric ARV formulary and limited use list: 2016 Update. http://apps.who.int/medicinedocs/documents/s23120en/s23120en.pdf, 2016 (accessed Sept 29, 2017).
31. Eholie, SP, Badje, A, Kouame, GM, et al. Antiretroviral treatment regardless of CD4 count: the universal answer to a contextual question. AIDS Res Ther, 13, 2016, 27.
32. Gupta, S, Granich, R, Suthar, AB, et al. Global policy review of antiretroviral therapy eligibility criteria for treatment and prevention of HIV and tuberculosis in adults, pregnant women, and serodiscordant couples. J Acquir Immune Defic Syndr 62 (2013), e87–e97.
33. Cohen, MS, Chen, YQ, McCauley, M, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med 375 (2016), 830–839.
34. O'Connor, J, Vjecha, MJ, Phillips, AN, et al. Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial. Lancet HIV 4 (2017), e105–e112.
35. Anglemyer, A, Rutherford, GW, Easterbrook, PJ, et al. Early initiation of antiretroviral therapy in HIV-infected adults and adolescents: a systematic review. AIDS 28:suppl 2 (2014), S105–S118.
36. WHO. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV, 2015, World Health Organization, Geneva.
37. Ford, N, Meintjes, G, Pozniak, A, et al. The future role of CD4 cell count for monitoring antiretroviral therapy. Lancet Infect Dis 15 (2015), 241–247.
38. Ford, N, Nsanzimana, S, Accelerating initiation of antiretroviral therapy. Lancet HIV 11 (2016), e504–e505.
39. Vitoria, M, Vella, S, Ford, N, Scaling up antiretroviral therapy in resource-limited settings: adapting guidance to meet the challenges. Curr Opin HIV AIDS 8 (2013), 12–18.
40. Peter, T, Ellenberger, D, Kim, AA, et al. Early antiretroviral therapy initiation: access and equity of viral load testing for HIV treatment monitoring. Lancet Infect Dis 17 (2017), e26–e29.
41. Reidy, WJ, Sheriff, M, Wang, C, et al. Decentralization of HIV care and treatment services in Central Province, Kenya. J Acquir Immune Defic Syndr 67 (2014), e34–e40.
42. Auld, AF, Kamiru, H, Azih, C, et al. Implementation and operational research: evaluation of Swaziland's Hub-and-Spoke model for decentralizing access to antiretroviral therapy services. J Acquir Immune Defic Syndr 69 (2015), e1–e12.
43. Abongomera, G, Kiwuwa-Muyingo, S, Revill, P, et al. Population level usage of health services, and HIV testing and care, prior to decentralization of antiretroviral therapy in Agago District in rural Northern Uganda. BMC Health Serv Res, 15, 2015, 527.
44. Auld, AF, Nuwagaba-Biribonwoha, H, Azih, C, et al. Decentralizing access to antiretroviral therapy for children living with HIV in Swaziland. Pediatr Infect Dis J 35 (2016), 886–893.
45. Vogt, F, Kalenga, L, Lukela, J, et al. Brief report: decentralizing ART supply for stable HIV patients to community-based distribution centers: program outcomes from an urban context in Kinshasa, DRC. J Acquir Immune Defic Syndr 74 (2017), 326–331.
46. Low, AJ, Mburu, G, Welton, NJ, et al. Impact of opioid substitution therapy on antiretroviral therapy outcomes: a systematic review and meta-analysis. Clin Infect Dis 63 (2016), 1094–1104.
47. Suthar, AB, Hoos, D, Beqiri, A, Lorenz-Dehne, K, McClure, C, Duncombe, C, Integrating antiretroviral therapy into antenatal care and maternal and child health settings: a systematic review and meta-analysis. Bull World Health Organ 91 (2013), 46–56.
48. Uyei, J, Coetzee, D, Macinko, J, Guttmacher, S, Integrated delivery of HIV and tuberculosis services in sub-Saharan Africa: a systematic review. Lancet Infect Dis 11 (2011), 855–867.
49. WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach, 2nd edn., 2016, World Health Organization, Geneva.
50. Kober, K, Van Damme, W, Scaling up access to antiretroviral treatment in southern Africa: who will do the job?. Lancet 364 (2004), 103–107.
51. Jahn, A, Harries, AD, Schouten, E, et al. Scaling-up antiretroviral therapy in Malawi. Bull World Health Organ 94 (2016), 772–776.
52. Sanne, I, Orrell, C, Fox, MP, et al. Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet 376 (2010), 33–40.
53. Suzan-Monti, M, Blanche, J, Boyer, S, et al. Benefits of task-shifting HIV care to nurses in terms of health-related quality of life in patients initiating antiretroviral therapy in rural district hospitals in Cameroon [Stratall Agence Nationale de Recherche sur le SIDA (ANRS) 12110/Ensemble pour une Solidarite Therapeutique Hospitaliere en Reseau (ESTHER) substudy]. HIV Med 16 (2015), 307–318.
54. Penazzato, M, Davies, MA, Apollo, T, Negussie, E, Ford, N, Task shifting for the delivery of pediatric antiretroviral treatment: a systematic review. J Acquir Immune Defic Syndr 65 (2014), 414–422.
55. Boyer, S, Marcellin, F, Ongolo-Zogo, P, et al. Financial barriers to HIV treatment in Yaounde, Cameroon: first results of a national cross-sectional survey. Bull World Health Organ 87 (2009), 279–287.
56. McGuire, M, Munyenyembe, T, Szumilin, E, et al. Vital status of pre-ART and ART patients defaulting from care in rural Malawi. Trop Med Int Health 15:suppl 1 (2010), 55–62.
57. Kouanda, S, Bocoum, FY, Doulougou, B, et al. User fees and access to ARV treatment for persons living with HIV/AIDS: implementation and challenges in Burkina Faso, a limited-resource country. AIDS Care 22 (2010), 1146–1152.
58. Moon, S, Van Leemput, L, Durier, N, et al. Out-of-pocket costs of AIDS care in China: are free antiretroviral drugs enough?. AIDS Care 20 (2008), 984–994.
59. Tran, BX, Duong, AT, Nguyen, LT, et al. Financial burden of health care for HIV/AIDS patients in Vietnam. Trop Med Int Health 18 (2013), 212–218.
60. The Global Fund PEPFAR, Republic of South Africa. Consolidated demand outlook. Large ARV buyers and sellers Forum. https://www.theglobalfund.org/media/5836/psm_2016-11-arvbuyersellersforum_presentation_en.pdf, 2016 (accessed Sept 29, 2017).
61. WHO. Harmonized monitoring and evaluation indicators for procurement and supply management systems. Early-warning indicators to prevent stock-outs and overstocking of antiretroviral, antituberculosis and antimalaria medicines, 2011, World Health Organization, Geneva http://apps.who.int/iris/bitstream/10665/44546/1/9789241500814_eng.pdf (accessed Sept 29, 2017).
62. WHO. Consolidated strategic information guidelines for HIV in the health sector, 2015, World Health Organization, Geneva.
63. UNAIDS. 90-90-90—an ambitious treatment target to help end the AIDS epidemic, 2014, The Joint United Nations Programme on HIV/AIDS, Geneva.
64. Ford, N, Shubber, Z, Meintjes, G, et al. Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis. Lancet HIV 2 (2015), e438–e444.
65. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach, 2nd edn., 2016, World Health Organization, Geneva.
66. Cohn, J, Whitehouse, K, Tuttle, J, Lueck, K, Tran, T, Paediatric HIV testing beyond the context of prevention of mother-to-child transmission: a systematic review and meta-analysis. Lancet HIV 3 (2016), e473–e481.
67. Patel, DA, Snedecor, SJ, Tang, WY, et al. 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis. PLoS One, 9, 2014, e105653.
68. ENCORE1 Study Group. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet 383 (2014), 1474–1482.
69. Vitoria, M, Ford, N, Clayden, P, Pozniak, AL, Hill, AM, When could new antiretrovirals be recommended for national treatment programmes in low-income and middle-income countries: results of a WHO Think Tank. Curr Opin HIV AIDS 12 (2017), 414–422.
70. Margolis, D, González-García, J, Stellbrink, H-J, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet 390 (2017), 1499–1510.
71. Bonner, K, Mezochow, A, Roberts, T, Ford, N, Cohn, J, Viral load monitoring as a tool to reinforce adherence: a systematic review. J Acquir Immune Defic Syndr 64 (2013), 74–78.
72. The BREATHER (PENTA 16) Trial Group. Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial. Lancet HIV 3 (2016), e421–e430.
73. Achhra, AC, Mwasakifwa, G, Amin, J, Boyd, MA, Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis. Lancet HIV 3 (2016), e351–e360.
74. Boffito, M, Jackson, A, Owen, A, Becker, S, New approaches to antiretroviral drug delivery: challenges and opportunities associated with the use of long-acting injectable agents. Drugs 74 (2014), 7–13.
75. Hanrahan, CF, Clouse, K, Bassett, J, et al. The patient impact of point-of-care vs laboratory placement of Xpert MTB/RIF. Int J Tuberc Lung Dis 19 (2015), 811–816.
76. Vojnov, L, Markby, J, Boeke, C, Harris, L, Ford, N, Peter, T, POC CD4 testing improves linkage to HIV care and timeliness of ART initiation in a public health approach: a systematic review and meta-analysis. PLoS One, 11, 2016, e0155256.
77. Roberts, T, Cohn, J, Bonner, K, Hargreaves, S, Scale-up of routine viral load testing in resource-poor settings: current and future implementation challenges. Clin Infect Dis 62 (2016), 1043–1048.
78. Wilkinson, LS, Skordis-Worrall, J, Ajose, O, Ford, N, Self-transfer and mortality amongst adults lost to follow-up in ART programmes in low- and middle-income countries: systematic review and meta-analysis. Trop Med Int Health 20 (2015), 365–379.
79. Fox, MP, Rosen, S, Geldsetzer, P, Barnighausen, T, Negussie, E, Beanland, R, Interventions to improve the rate or timing of initiation of antiretroviral therapy for HIV in sub-Saharan Africa: meta-analyses of effectiveness. J Int AIDS Soc, 19, 2016, 20888.
80. Nachega, JB, Adetokunboh, O, Uthman, OA, et al. Community-based interventions to improve and sustain antiretroviral therapy adherence, retention in HIV care and clinical outcomes in low- and middle-income countries for achieving the UNAIDS 90-90-90 targets. Curr HIV/AIDS Rep 13 (2016), 241–255.
81. Habiyambere, V, Ford, N, Low-Beer, D, et al. Availability and use of HIV monitoring and early infant diagnosis technologies in WHO member states in 2011–2013: analysis of annual surveys at the facility level. PLoS Med, 13, 2016, e1002088.
82. Boender, TS, Sigaloff, KC, McMahon, JH, et al. Long-term virological outcomes of first-line antiretroviral therapy for HIV-1 in low- and middle-income countries: a systematic review and meta-analysis. Clin Infect Dis 61 (2015), 1453–1461.
83. WHO. HIV drug resistance report 2017, 2017, World Health Organization, Geneva http://www.who.int/hiv/pub/drugresistance/hivdr-report-2017/en/ (accessed Sept 29, 2017).
84. WHO. HIV drug resistance surveillance guidance: 2015 update, 2015, World Health Organization, Geneva.
85. WHO. Guidelines on the public health response to pretreatment HIV drug resistance, 2017, World Health Organization, Geneva.
86. Decroo, T, Rasschaert, F, Telfer, B, Remartinez, D, Laga, M, Ford, N, Community-based antiretroviral therapy programs can overcome barriers to retention of patients and decongest health services in sub-Saharan Africa: a systematic review. Int Health 5 (2013), 169–179.
87. Bango, F, Ashmore, J, Wilkinson, L, van Cutsem, G, Cleary, S, Adherence clubs for long-term provision of antiretroviral therapy: cost-effectiveness and access analysis from Khayelitsha, South Africa. Trop Med Int Health 21 (2016), 1115–1123.
88. Grimsrud, A, Lesosky, M, Kalombo, C, Bekker, LG, Myer, L, Implementation and operational research: community-based adherence clubs for the management of stable antiretroviral therapy patients in Cape Town, South Africa: a cohort study. J Acquir Immune Defic Syndr 71 (2016), e16–e23.
89. Duncombe, C, Rosenblum, S, Hellmann, N, et al. Reframing HIV care: putting people at the centre of antiretroviral delivery. Trop Med Int Health 20 (2015), 430–447.
90. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach, 2nd edn., 2016, World Health Organization, Geneva.
91. Mutasa-Apollo, T, Ford, N, Wiens, M, et al. Effect of frequency of clinic visits and medication pick-up on antiretroviral treatment outcomes: a systematic literature review and meta-analysis. J Int AIDS Soc 20:suppl 4 (2017), 88–98.
92. Hakim, J, Musiime, V, Szubert, AJ, et al. Enhanced prophylaxis plus antiretroviral therapy for advanced HIV infection in Africa. N Engl J Med 377 (2017), 233–245.
93. Mfinanga, S, Chanda, D, Kivuyo, SL, et al. Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial. Lancet 385 (2015), 2173–2182.
94. GBD 2013 MCDC. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385 (2015), 117–171.
95. Stanaway, JD, Flaxman, AD, Naghavi, M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 388 (2016), 1081–1088.
96. Haldane, V, Legido-Quigley, H, Chuah, FLH, et al. Integrating cardiovascular diseases, hypertension, and diabetes with HIV services: a systematic review. AIDS Care 5 (2017), 1–13.
97. WHO. Global report on early warning indicators of HIV drug resistance, 2016, World Health Organization, Geneva.
98. Iwuji C, Orne-Gliemann J, Balestre E, Larmarange J, Thiebaut R, Tanser F. The impact of universal test and treat on HIV incidence in a rural South African population: ANRS 12249 TasP trial, 2012–2016. 21st International AIDS Conference; Durban, South Africa; July 18–22, 2016. FRAC0105LB.
99. Fox, MP, Rosen, S, Retention of adult patients on antiretroviral therapy in low- and middle-income countries: systematic review and meta-analysis 2008–2013. J Acquir Immune Defic Syndr 69 (2015), 98–108.
100. Fox, MP, Rosen, S, A new cascade of HIV care for the era of “treat all”. PLoS Med, 14, 2017, e1002268.
101. Govindasamy, D, Ford, N, Kranzer, K, Risk factors, barriers and facilitators for linkage to antiretroviral therapy care: a systematic review. AIDS 26 (2012), 2059–2067.
102. Bateganya, MH, Amanyeiwe, U, Roxo, U, Dong, M, Impact of support groups for people living with HIV on clinical outcomes: a systematic review of the literature. J Acquir Immune Defic Syndr 68:suppl 3 (2015), S368–S374.
103. Bemelmans, M, Baert, S, Negussie, E, et al. Sustaining the future of HIV counselling to reach 90-90-90: a regional country analysis. J Int AIDS Soc, 19, 2016, 20751.
104. Mathers, BM, Degenhardt, L, Ali, H, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 375 (2010), 1014–1028.
105. DeBeck, K, Cheng, T, Montaner, JS, et al. HIV and the criminalisation of drug use among people who inject drugs: a systematic review. Lancet HIV 8 (2017), e357–e374.
106. WHO. Transgender people and HIV: policy brief, 2015, World Health Organization, Geneva.
107. Kamarulzaman, A, Reid, SE, Schwitters, A, et al. Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners. Lancet 388 (2016), 1115–1126.
108. Beyrer, C, Crago, AL, Bekker, LG, et al. An action agenda for HIV and sex workers. Lancet 385 (2015), 287–301.
109. Beyrer, C, Baral, SD, Collins, C, et al. The global response to HIV in men who have sex with men. Lancet 388 (2016), 198–206.
110. Beyrer, C, Sullivan, PS, Sanchez, J, et al. A call to action for comprehensive HIV services for men who have sex with men. Lancet 380 (2012), 424–438.
111. Siegfried, N, Muller, M, Deeks, JJ, Volmink, J, Male circumcision for prevention of heterosexual acquisition of HIV in men. Cochrane Database Syst Rev, 2, 2009 CD003362.
112. Fonner, VA, Dalglish, SL, Kennedy, CE, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS 30 (2016), 1973–1983.
113. Anglemyer, A, Rutherford, GW, Horvath, T, Baggaley, RC, Egger, M, Siegfried, N, Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev, 4, 2013 CD009153.
114. Baggaley, R, Dalal, S, Johnson, C, et al. Beyond the 90-90-90: refocusing HIV prevention as part of the global HIV response. J Int AIDS Soc, 19, 2016, 21348.
115. Wariki, WM, Ota, E, Mori, R, Koyanagi, A, Hori, N, Shibuya, K, Behavioral interventions to reduce the transmission of HIV infection among sex workers and their clients in low- and middle-income countries. Cochrane Database Syst Rev, 2, 2012 CD005272.
116. Johnson, WD, Diaz, RM, Flanders, WD, et al. Behavioral interventions to reduce risk for sexual transmission of HIV among men who have sex with men. Cochrane Database Syst Rev, 3, 2008 CD001230.
117. Kennedy, CE, Medley, AM, Sweat, MD, O'Reilly, KR, Behavioural interventions for HIV positive prevention in developing countries: a systematic review and meta-analysis. Bull World Health Organ 88 (2010), 615–623.
118. Jay, J, Buse, K, Hart, M, et al. Building from the HIV Response toward Universal Health Coverage. PLoS Med, 13, 2016, e1002083.
119. WHO. HIV, Universal health coverage and the post-2015 development agenda. A discussion paper, 2014, World Health Organization, Geneva.
120. Frieden, TR, Foti, KE, Mermin, J, Applying public health principles to the HIV epidemic—how are we doing?. N Engl J Med 373 (2015), 2281–2287.